Definium Therapeutics, Inc.

Definium Therapeutics, Inc. is a clinical biopharmaceutical company dedicated to developing novel product candidates for the treatment of brain health disorders. The company's mission is to advance a new era of psychiatry by applying scientific rigor to psychedelic and psychoplastogenic drugs, aiming to create accessible treatments that address the underlying causes of psychiatric and neurological conditions. Headquartered at One World Trade Center, Suite 8500, New York, NY, United States, Definium Therapeutics seeks to transform mental healthcare by delivering long-term remission rather than merely reducing symptoms.

The company's pipeline primarily features two lead product candidates: DT120 ODT (lysergide tartrate, formerly MM120) and DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine, formerly MM402). DT120 ODT is currently in Phase 3 clinical trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD), while DT402 is in Phase 2a clinical trials for autism spectrum disorder (ASD). Definium Therapeutics focuses on drug development, psychedelic research, and psychedelic-assisted therapy to target these significant market segments.

Definium Therapeutics, formerly known as Mind Medicine (MindMed) Inc., rebranded in January 2026, signaling a strategic shift towards late-stage biotech. Robert Barrow serves as the Chief Executive Officer, and Brandi Roberts is the Chief Financial Officer. The company has received FDA Breakthrough Therapy Designation for DT120 ODT in GAD and anticipates key Phase 3 data readouts for DT120 ODT in GAD and MDD, as well as initial Phase 2a data for DT402 in ASD, throughout 2026. Definium Therapeutics has also publicly supported the White House Executive Order aimed at accelerating mental health innovation and expanding access to psychedelic medical treatments.